TG Therapeutics (NASDAQ:TGTX) Director Laurence Charney Sells 5,000 Shares

TG Therapeutics, Inc. (NASDAQ:TGTX) Director Laurence Charney sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the transaction, the director owned 168,640 shares of the company’s stock, valued at $9,268,454.40. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

TG Therapeutics Stock Up 0.2%

NASDAQ TGTX traded up $0.11 during trading hours on Monday, reaching $54.00. 1,362,161 shares of the company’s stock were exchanged, compared to its average volume of 2,177,618. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. The company has a market capitalization of $8.27 billion, a price-to-earnings ratio of 19.71, a price-to-earnings-growth ratio of 2.31 and a beta of 1.67. The company’s 50-day moving average is $53.64 and its two-hundred day moving average is $43.77. TG Therapeutics, Inc. has a one year low of $26.76 and a one year high of $59.30.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The company had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business’s quarterly revenue was up 70.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.17 EPS. On average, analysts forecast that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

Hedge Funds Weigh In On TG Therapeutics

Several hedge funds have recently modified their holdings of TGTX. EverSource Wealth Advisors LLC raised its holdings in TG Therapeutics by 51.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 365 shares in the last quarter. Hantz Financial Services Inc. grew its stake in TG Therapeutics by 82.7% in the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 560 shares in the last quarter. Harbor Investment Advisory LLC acquired a new position in shares of TG Therapeutics during the 2nd quarter worth approximately $96,000. Covestor Ltd increased its position in shares of TG Therapeutics by 563.0% during the 4th quarter. Covestor Ltd now owns 1,810 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 1,537 shares during the last quarter. Finally, Pingora Partners LLC raised its stake in shares of TG Therapeutics by 31.2% during the 4th quarter. Pingora Partners LLC now owns 2,100 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 500 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TGTX. HC Wainwright reaffirmed a “buy” rating and issued a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday, September 1st. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a report on Wednesday, July 29th. Jefferies Financial Group reissued a “buy” rating and issued a $83.00 target price on shares of TG Therapeutics in a research report on Monday, June 22nd. B. Riley Financial boosted their target price on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Finally, JPMorgan Chase & Co. upped their price target on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $63.00.

About TG Therapeutics

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company’s research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.

TG Therapeutics’ principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.